The short answer
The behavioural interest in this sequence predates Semax by two decades. Dornbush and colleagues published on ACTH 4-10 and short-term memory in 1976, and Sandman and colleagues on MSH/ACTH 4-10 and measures of attention in 1977.
Key facts
- Dornbush 1976
- Pharmacol Biochem Behav (PMID 189333)
- Sandman 1977
- J Clin Endocrinol Metab (PMID 192754)
- Fragment studied
- ACTH(4-10) itself, not an analogue
- Domains examined
- Short-term memory, attention
- Why a fragment
- Separating behaviour from steroid release
- Semax came later
- As a stabilised analogue
Why anyone tested a fragment of a stress hormone
ACTH's main job is stimulating adrenal steroid release. Observations that it also affected behaviour raised an obvious question: was that a consequence of the steroids, or a direct effect? Testing a fragment too short to drive adrenal stimulation was the way to separate the two, which is why attention turned to residues 4 to 10 specifically.
What the fragment offered
A sequence retaining whatever was behaviourally active while lacking the portions required for the endocrine effect. If a fragment produced behavioural changes without the hormonal ones, the behavioural effect could not be attributed to steroid release. That is a clean experimental logic and it is why this particular fragment became a research object.
Research material referenced
Semax 10mg, third-party HPLC tested
What was measured
Dornbush and colleagues examined short-term memory in 1976. Sandman and colleagues examined behavioural and physiological measures of attention in 1977, publishing in the Journal of Clinical Endocrinology and Metabolism. Attention and memory are the two domains this literature has concerned itself with ever since.
Why the research did not simply continue
Native ACTH(4-10) is a short unmodified peptide with no protection against peptidases, so its duration is very limited. A fragment that is interesting but degrades almost immediately is difficult to develop further, and that practical obstacle is what later analogue design set out to address.
How Semax relates to that history
Semax retains positions 4 to 7 of the fragment and replaces what followed with Pro-Gly-Pro, a motif chosen for peptidase resistance. It is a response to the durability problem rather than a new pharmacological idea; the question it was built to pursue is the one the 1970s work posed.
How to weigh 1970s behavioural data
Cautiously. Studies from that period generally involved small numbers, and reporting standards for randomisation, blinding and pre-specified endpoints were considerably looser than current expectations. They establish that a question was asked seriously and found interesting; they do not carry the evidential weight a modern trial would.
Frequently asked questions
Why study a fragment rather than ACTH itself?
To separate behavioural effects from adrenal steroid release. A fragment too short to drive the endocrine effect isolates the question.
What did the 1970s studies examine?
Short-term memory (Dornbush 1976) and behavioural and physiological measures of attention (Sandman 1977).
Why did Semax follow?
Native ACTH(4-10) degrades rapidly. Semax replaces positions 8 to 10 with Pro-Gly-Pro, a peptidase-resistant motif.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDornbush RL et al., ACTH 4-10 and short-term memory. Pharmacol Biochem Behav 1976 (PMID 189333)pubmed.ncbi.nlm.nih.gov
- PubMedSandman CA et al., MSH/ACTH 4-10 influences behavioral and physiological measures of attention. J Clin Endocrinol Metab 1977 (PMID 192754)pubmed.ncbi.nlm.nih.gov
- PubMedDores RM: Ann N Y Acad Sci 2011 (PMID 21388402)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- What the Melanocortin Neuroprotection Literature ReportsCatania 2008 reviewed neuroprotective actions of melanocortins. Giuliani 2006 examined MC4R-stimulating melanocortins in cerebral ischaemia models.
- A Mechanism Layer Below Gene ExpressionKolbaev 2025 examined Semax and calcium dynamics in rat brain neurons - a faster timescale than the neurotrophin expression work.
- What the Animal Behavioural Work ReportsGlazova 2021 examined Semax against alterations following early-life fluvoxamine exposure in rats. Why the model design is the interesting part.
- What a Fragment Keeps Decides What It DoesThree fragments of alpha-MSH pursue pigmentation, inflammation and cognition. The difference is not the parent - it is which residues each retained.
- What Is Semax? Origin, Sequence and Neurotrophin MechanismSemax is a synthetic heptapeptide derived from an ACTH fragment, developed in Russia. Structure, neurotrophin mechanism and regulatory status.